Log in

Relevant bibliographies by topics / 159. 922: 808. 51 (043.2)

Contents

Journal articles

Academic literature on the topic '159. 922: 808. 51 (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '159. 922: 808. 51 (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "159. 922: 808. 51 (043.2)"

1

Fleischmann, R., M. C. Genovese, K. Maslova, H. Leher, A. Praestgaard, and G. R. Burmester. "FRI0092 LONG-TERM SAFETY AND EFFICACY OF SARILUMAB OVER 5 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS REFRACTORY TO TUMOR NECROSIS FACTOR INHIBITORS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 624–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1946.

Full text

Abstract:

Background:Sarilumab is a human IL-6 receptor (IL-6R) inhibitor approved for the treatment of adults with moderate to severely active rheumatoid arthritis (RA). In the TARGET study (NCT01709578), sarilumab plus conventional synthetic disease-modifying antirheumatic drugs (DMARDs) significantly improved signs and symptoms of RA and physical function versus placebo in patients refractory to tumor necrosis factor (TNF) inhibitors.Objectives:Here we report the long-term safety and efficacy of subcutaneous (SC) sarilumab over 5 years in patients who continued treatment in the open-label extension s

APA, Harvard, Vancouver, ISO, and other styles

2

Abacar, K., Ş. Çolakoğlu Özkaya, E. Biyikli, O. Buğdayci, P. Atagündüz, and Z. D. Selcuk. "POS1198-HPR PREVALENCE OF INFLAMMATORY BACK PAIN IN PRIMARY SJOGREN’S SYNDROME IS INCREASED AND ASSOCIATED WITH ACUTE AND STRUCTURAL CHANGES OF THE SACROILIAC JOINT." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 931.2–931. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6491.

Full text

Abstract:

BackgroundAn increased prevalence of axial articular manifestations has recently been reported in primary Sjögren‘s syndrome (pSS).[1]Radiologic findings associated with inflammatory back pain (IBP) are not well documented in pSS patients.ObjectivesTo assess the prevalence of IBP and its association with magnetic resonance imaging (MRI) detected acute inflammatory and structural changes of sacroiliitis in pSS patients with IBP.MethodsIn this cross-sectional study, consecutive pSS patients fulfilling ACR/EULAR classification criteria and age- and sex-matched healthy controls (HC) were screened

APA, Harvard, Vancouver, ISO, and other styles

3

Hens, Luc, Nguyen An Thinh, Tran Hong Hanh, et al. "Sea-level rise and resilience in Vietnam and the Asia-Pacific: A synthesis." VIETNAM JOURNAL OF EARTH SCIENCES 40, no. 2 (2018): 127–53. http://dx.doi.org/10.15625/0866-7187/40/2/11107.

Full text

Abstract:

Climate change induced sea-level rise (SLR) is on its increase globally. Regionally the lowlands of China, Vietnam, Bangladesh, and islands of the Malaysian, Indonesian and Philippine archipelagos are among the world’s most threatened regions. Sea-level rise has major impacts on the ecosystems and society. It threatens coastal populations, economic activities, and fragile ecosystems as mangroves, coastal salt-marches and wetlands. This paper provides a summary of the current state of knowledge of sea level-rise and its effects on both human and natural ecosystems. The focus is on coastal urban

APA, Harvard, Vancouver, ISO, and other styles

4

Hong, Seung Pyo, Min Jeong Kim, Allison Belette, Youjin Oh, Sukjoo Cho, and Young Kwang Chae. "238 Meta-analysis on the incidence of hyperprogressive disease during immune checkpoint inhibitor therapy." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A254—A256. http://dx.doi.org/10.1136/jitc-2021-sitc2021.238.

Full text

Abstract:

BackgroundHyperprogressive disease (HPD) is a distinct pattern of rapid tumor progression observed in patients with cancer who are undergoing immune checkpoint inhibitor therapy. Despite the growing evidence, a universal definition of HPD remains to be established, and incidence rates vary based on the defining criteria. Therefore, a refinement of currently existing criteria is warranted to better characterize this phenomenon and evaluate its incidence.MethodsTwo independent investigators performed a systematic literature search in EMBASE and MEDLINE using keywords selected in Park et al.1: ch

APA, Harvard, Vancouver, ISO, and other styles

5

Dolomatov, S.I., та W. Zukow. "Эпигенетика почек = Kidneys epigenetics". 7 липня 2019. https://doi.org/10.5281/zenodo.3270754.

Full text

Abstract:

<strong>Dolomatov S.I., Zukow W. </strong><strong>Эпигенетика почек</strong><strong> = Kidney</strong><strong>s</strong><strong> epigenetics</strong><strong>. </strong><strong>RSW. Radom,</strong><strong> 144 </strong><strong>p. ISBN </strong><strong>9780359774524</strong><strong>.</strong><strong> DOI </strong><strong>http://dx.doi.org/10.5281/zenodo.3270699</strong><strong> PBN Poland </strong><strong>https://pbn.nauka.gov.pl/sedno-webapp/works/917606</strong>           <strong>Radomska Szkoła Wyższa w Radomiu, Radom, Poland</strong>         &nbsp

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!